Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 4/2000

01-07-2000

The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma

Authors: Martin Hagenaars, Ron Koelemij, N. Geeske Ensink, Jaap D.H. van Eendenburg, Ronald L.P. van Vlierberghe, Alexander M.M. Eggermont, Cornelis J.H. van de Velde, Gert Jan Fleuren, Peter J.K. Kuppen

Published in: Clinical & Experimental Metastasis | Issue 4/2000

Login to get access
Metadata
Title
The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma
Authors
Martin Hagenaars
Ron Koelemij
N. Geeske Ensink
Jaap D.H. van Eendenburg
Ronald L.P. van Vlierberghe
Alexander M.M. Eggermont
Cornelis J.H. van de Velde
Gert Jan Fleuren
Peter J.K. Kuppen
Publication date
01-07-2000
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 4/2000
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1011062002851

Other articles of this Issue 4/2000

Clinical & Experimental Metastasis 4/2000 Go to the issue

OriginalPaper

Venesection needle coring increases positive results with RT-PCR for detection of circulating cells expressing CEA mRNA

OriginalPaper

Nitric oxide (NO), methylation and TIMP-1 expression in BL6 melanoma cells transfected with MHC class I genes

OriginalPaper

Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion

OriginalPaper

Membrane-type 1 matrix metalloproteinase enhances lymph node metastasis of gastric cancer

OriginalPaper

Liver metastatic ability of human melanoma cell line is associated with losses of chromosomes 4, 9p21-pter and 10p

OriginalPaper

Inhibitory effect of 1-O (2 methoxy) hexadecyl glycerol and phenylbutyrate on the malignant properties of human prostate cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits